Want to join the conversation?
$ENTA said the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for $ABBV's investigational chronic hepatitis C virus (HCV) regimen. Glecaprevir (GLE) is $ENTA's second protease inhibitor being developed through its collaboration with $ABBV.
$MCD stock rose more than 2% after it posted better than expected 3Q16 results, driven by global same-store sales growth. Meanwhile, earnings and revenue were lower than last year, hurt by refranchising efforts.
$RAI has received a $47 billion take over offer from British tobacco giant British American Tobacco! This is huge!
No better outlook on $MSFT. Even if the results beat a bit, the stock may move 4 to 6% higher, but won't go above $60.